Ritlecitinib: Alopecia
The question
To ask the Secretary of State for Health and Social Care, whether he plans to update guidance on the use of Ritlecitinib to treat alopecia.
Answered by Karin Smyth
The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations for the National Health Service in England on the use of new medicines, based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines recommended in NICE technology appraisal guidance, normally within three months of the publication of final guidance.
The NICE issued guidance in March 2024 that recommends ritlecitinib, within its marketing authorisation, as an option for treating severe alopecia areata in people 12 years old and over. Whilst severity is not specifically defined in the guidance, the evidence submission by the medicine’s manufacturer defined ‘severe’ as a Severity of Alopecia Tool score of more than 50 out of 100. The guidance also acknowledges that living with severe alopecia areata can have a profound impact on psychosocial health. At the present time, there are no plans to update this guidance.
As health is a devolved issue, information relating to guidance on the use of ritlecitinib in Scotland would be held by the Scottish health authorities.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →